<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185845</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1304402B</org_study_id>
    <nct_id>NCT03185845</nct_id>
  </id_info>
  <brief_title>The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism</brief_title>
  <official_title>The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism—— A National Multicenter, Prospective, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticoagulation is the most important treatment for pulmonary thromboembolism (PTE). The
      thromboembolism risk is especially high in patients with chronic obstructive pulmonary
      disease (COPD) exacerbations. However, there's no agreement on the most appropriate duration
      of anticoagulation in COPD with PTE to balance the risk of recurrence of thrombosis and
      bleeding. This randomized, controlled trial aims to evaluate the risk and benefit of
      prolonged anticoagulation compared with the regular 3-month anticoagulation in COPD with PTE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>recurrence rate in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic obstructive pulmonary disease exacerbations</measure>
    <time_frame>3 year</time_frame>
    <description>total times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>COPD Exacerbation</condition>
  <condition>PTE - Pulmonary Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Prolonged anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 months longer anticoagulation after regular treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular anticoagulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>stop anticoagulation after regular treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>tailored dose according to international normalized ratio (INR) for 3 months</description>
    <arm_group_label>Prolonged anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized patients due to chronic obstructive pulmonary disease exacerbation and
             diagnosed as newly developed pulmonary thromboembolism

          -  Regular anticoagulation for 3 months and got CT pulmonary angiography

        Exclusion Criteria:

          -  Patients with major bleeding during prior anticoagulation

          -  Patients need long term anticoagulation to treat other diseases

          -  Patients unwilling to receive prolonged anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuanhua Yang, MD</last_name>
    <phone>13911773607</phone>
    <email>yyh1031@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100043</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanhua Yang, MD</last_name>
      <phone>13911773607</phone>
      <email>yyh1031@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Jianguo He</investigator_full_name>
    <investigator_title>Chief of Pulmonary Vascular Disease Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

